Franziska Duckstein

Meine fünf wichtigsten Publikationen:

1. Januar 2023: Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis.
Caley LR, Zagoya C, Duckstein F, White H, Shimmin D, Jones AM, Barrett J, Whitehouse JL, Floto RA, Mainz JG, Peckham DG. J Cyst Fibros. 2023 Jan 27:S1569-1993(23)00018-8.

2. Juni 2022: Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score.
Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duck-stein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D, Schwarz C.Front Immunol. 2021 May 5;12:642180.

3. Mai 2021: Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining FluidMai 2021 Frontiers in Immunology.
Jochen G Mainz, Christin Arnold, Kara Wittstock, Uta-Christina Hipler, Thomas Lehmann, Carlos Zagoya, Franziska Duckstein, Helmut Ellemunter, Julia Hentschel

4. März 2021: Would it have happened without Christmas? Thoracic emphysema and Allergic Bron-chopulmonary Aspergillosis in a juvenile CF-patient with G551D receiving ivacaftor
ERJ Open Research
Jochen G. Mainz, Nina Erdmann, Franziska Duckstein, Carlos Zagoya

5. März 2021: Would it have happened without Christmas? Thoracic emphysema and Allergic Bron-chopulmonary Aspergillosis in a juvenile CF-patient with G551D receiving ivacaftor
ERJ Open Research
Jochen G. Mainz, Nina Erdmann, Franziska Duckstein, Carlos Zagoya

Weitere/Alle Publikationen:
Link zu pubmed: https://pubmed.ncbi.nlm.nih.gov/?term=Franziska+Duckstein